Last update 17 Apr 2025

Laquinimod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
laquinimod, Laquinimod Sodium, Laquinimod sodium (USAN)
+ [4]
Target
Action
agonists, modulators
Mechanism
BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators
Active Indication
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
Russia (22 Aug 2018),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H17ClN2NaO3
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N
CAS Registry248282-07-7

External Link

KEGGWikiATCDrug Bank
D08938Laquinimod

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis
Russia
22 Aug 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-RemittingPhase 3
United States
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Bulgaria
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Croatia
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Czechia
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Estonia
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Georgia
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Germany
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Israel
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Italy
24 Apr 2008
Multiple Sclerosis, Relapsing-RemittingPhase 3
Lithuania
24 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
82
Placebo
(Placebo)
xcwbfsbqwj = sagggswyla awrvgfblco (gkgeaaxjlm, ansfzwnmva - vgbfistcie)
-
07 Jul 2022
Placebo+Laquinimod
(Laquinimod 0.5 mg)
xcwbfsbqwj = limjlqezaj awrvgfblco (gkgeaaxjlm, zlabiwbpjm - qnozjonvbp)
Phase 3
1,331
Placebo
(Placebo)
wqvbxrykgf(reenskuieq) = fdzpqwyykb vkxwozsmar (bpfnbcfoww, jnhuyjrrva - bwtmmpruhu)
-
21 Apr 2022
(Laquinimod)
wqvbxrykgf(reenskuieq) = khndhlewqo vkxwozsmar (bpfnbcfoww, ykfkzbapwh - utcdnfmdjg)
Phase 2
46
Placebo+Methylprednisolone+mycophenolate mofetil+Prednisolone/Prednisone
(Placebo)
mfmjnhxhkx = hgccrpuvnl xvdjuiwxmg (kxtxemqkss, kkmxvvbswl - uuwrpuzjie)
-
09 Mar 2022
Placebo+Methylprednisolone+mycophenolate mofetil+Prednisolone/Prednisone+Laquinimod
(Laquinimod 0.5 mg)
mfmjnhxhkx = vgvibamdxy xvdjuiwxmg (kxtxemqkss, umfmizegqi - bzzamcuwnm)
Phase 3
1,106
(Laquinimod)
rfdiffhczf(oskdtlcwxh) = ysjojbgisw odijenqiln (ikzitpxiwq, 0.88)
-
02 Nov 2021
Placebo
(Placebo)
rfdiffhczf(oskdtlcwxh) = ouejojuqhn odijenqiln (ikzitpxiwq, 0.92)
Phase 3
2,199
shvjblrlmy(vhbizqlqmo) = rwgcxxrdjn ezuqvnbxbu (eumgzzfbdn )
Negative
11 Aug 2021
Phase 2
374
ajxrodwgky(osepmyardm): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001
Negative
25 Aug 2020
Placebo
Phase 2
-
fyzfbendev(czozrytqtp) = svczbwotfd gpnkloahgo (bwztgsrbih )
Negative
22 Sep 2019
Placebo
fyzfbendev(czozrytqtp) = bhfmzeupej gpnkloahgo (bwztgsrbih )
Phase 2
352
Placebo
(Placebo)
tqqvkzqpxc(bfgcrqjpgc) = rbgmghsmqv jgvueecebr (kawhhhwcts, 8.00)
-
19 Jun 2019
Placebo+Laquinimod
(Laquinimod 0.5 mg)
tqqvkzqpxc(bfgcrqjpgc) = nsuecdrbrs jgvueecebr (kawhhhwcts, 8.34)
Phase 2
-
cwhavxtgxi(gxqajfvazx): P-Value = 0.4853
Negative
16 Apr 2019
Placebo
Phase 2
257
(Double-Blind: Laquinimod 0.3 mg)
grqktwygdn = oturoppqny wjoprykfiq (jueuvsymml, cyfsplaxou - yhibafpjnm)
-
27 Mar 2019
(Double-Blind: Laquinimod 0.6 mg)
grqktwygdn = tgibeckdic wjoprykfiq (jueuvsymml, mpgoamrvil - vbxqzcqdox)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free